Document is current
Any future updates will be listed below
-
Authors
Hashemian, Seyed-Mohammad Reza
Aliannejad, Rasoul
Zarrabi, Morteza
Soleimani, Masoud
Vosough, Massoud
Hosseini, Seyedeh-Esmat
Hossieni, Hamed
Keshel, Saeid Heidari
Naderpour, Zeinab
Hajizadeh-Saffar, Ensiyeh
Shajareh, Elham
Jamaati, Hamidreza
Soufi-Zomorrod, Mina
Khavandgar, Naghmeh
Alemi, Hediyeh
Karimi, Aliasghar
Pak, Neda
Rouzbahani, Negin Hossieni
Nouri, Masoumeh
Sorouri, Majid
Kashani, Ladan
Madani, Hoda
Aghdami, Nasser
Vasei, Mohammad
Baharvand, Hossein http://orcid.org/0000-0001-6528-3687
-
Funding
Funding for this research was provided by:
Tehran University of Medical Sciences (47136-97-1-99)
Iranian Council of Stem Cell Research and Technology (-)
Barkat Pharmaceutical Group Pharmed (-)
Royesh Venture Capital Fund (-)
- License Information
-
More Information
Article History
Received: 12 September 2020
Accepted: 12 January 2021
First Online: 29 January 2021
Ethics approval and consent to participate
: We obtained written informed consent from the conscious patients or first of kin of the unconscious patients. All procedures were conducted in accordance with the relevant approved regulations, guidelines, and the Declaration of Helsinki. The Ethical Committee of Tehran University of Medical Sciences (IR.TUMS.VCR.REC.1399.009) and the National Institute of Medical Research Development (IR.NIMAD.REC.1398.412) approved this study. The trial was registered as IRCT20200217046526N2 at the Iranian Registry of clinical trials.
: Not applicable.
: Massoud Vosough and Hossein Baharvand are regulatory affairs manager and member of the board of directors in CellTech Pharmed Company, respectively. They have no-share in this company.The other authors have no conflict of interest.
